John Choi
MD
pharmaceutical
Adagene
China
Biography
Dr. John Choi is a Venture Partner at Fidelity Growth Partners Asia and Fidelity Biosciences, where he is responsible for Fidelity’s healthcare portfolio, which includes Adagene. Dr. Choi has extensive experience as a healthcare investor, and executive and serial entrepreneur. He is a co-founder of Hua Medicine, another Fidelity company, as well as Pytho Capital, a research-oriented, life-science specialized hedge fund that invests in small-cap, public biotech companies. Before co-founding Pytho Capital, John was a Principal at the storied venture capital firm of Venrock Associates, the venture investing arm of the Rockefellers. During his tenure there, John focused on Venrock's biotechnology and medical device franchises, working actively with portfolio companies such as Coley Pharmaceuticals (acquired by Pfizer NYSE:PFE), Sirna Therapeutics (acquired by Merck NYSE: MRK), Celladon Corporation, and Princeton Lightwave. He was also previously involved with investments in Nanogram Devices Corporation (acquired by Wilson Greatbatch NYSE:GB), Targeted Genetics Corporation (NASDAQ:TGEN) and led the investment in Skinetics Biosciences (acquired by Sirna Therapeutics NASDAQ:RNAI). Prior to Venrock, he worked at the San Francisco offices of TVM Capital, an international venture capital firm with offices in the US and Europe.
Research Interest
pharmaceutical
